As a dispatch distributor, Fisher BioServices will offer cryogenic storage and will distribute Pluristem’s PLX cells for clinical trials and preclinical sites across the globe.
Pluristem is currently conducting clinical trials and preclinical studies for intermittent claudication, muscle regeneration, critical limb ischemia, Buerger’s disease and acute radiation syndrome.
Acute myocardial infarction (heart attack), lung disease and bone marrow disease clinical studies have resulted positively, according to the company.
The studies will be conducted in Europe, India, Israel and the US.
Pluristem chairman and CEO Zami Aberman said as the company expands its clinical trials for its PLX cell therapies for several indications, Pluristem needs a reliable distributor in cell therapy.
”Fisher BioServices was the clear choice for us because they are the world’s leader in biological materials handling and have supported hundreds of clinical trials," Aberman added.